This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moromizato, Y. Articles by Adamis, A. P. Search for Related Content PubMed PubMed Citation Articles by Moromizato, Y. Articles by Adamis, A. P.

(American Journal of Pathology. 2000;157:1277-1281.)
© 2000 American Society for Investigative Pathology

Regular Articles

CD18 and ICAM-1-Dependent Corneal Neovascularization and Inflammation after Limbal Injury

From the Laboratory for Surgical Research,^*
Children’s Hospital, Harvard Medical School, and the Department of Ophthalmology,
Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts

Extensive limbal injury is a leading cause of irreversible blindness. The destruction of corneal limbal stem cells often results in corneal neovascularization and an optically inferior epithelium. Previous work has shown that the neovascularization after limbal injury is vascular endothelial growth factor (VEGF)-dependent, with much of the VEGF emanating from the inflammatory cells that invade the cornea. Using a relevant mouse model of limbal injury, we examined the role of CD18 and intercellular adhesion molecule-1 (ICAM-1) in limbal injury-induced neovascularization. The results show that CD18- and ICAM-1-deficient mice developed 35% (n = 5, P = 0.003) and 36% (n = 5, P = 0.002) less neovascularization than strain-specific normal controls, respectively. The corneal neutrophil counts were similarly reduced by 51% (n = 5, P < 0.003) and 46% (n = 5, P < 0.006), respectively. When VEGF mRNA levels were analyzed, they were reduced by 66% (n = 3, P = 0.004) and 48% (n = 3, P = 0.024), respectively. Taken together, these data identify CD-18 and ICAM-1 as mediators of the inflammatory and VEGF-dependent corneal neovascularization that follows limbal injury. The targeting of CD18 and ICAM-1 may prove useful in the treatment of inflammation-associated neovascularization in the cornea and elsewhere.

This article has been cited by other articles:

				M. Ju, C. Mailhos, J. Bradley, T. Dowie, M. Ganley, G. Cook, P. Calias, N. Lange, A. P. Adamis, D. T. Shima, et al. Simultaneous but Not Prior Inhibition of VEGF165 Enhances the Efficacy of Photodynamic Therapy in Multiple Models of Ocular Neovascularization Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 662 - 670. [Abstract] [Full Text] [PDF]

				N. Jo, C. Mailhos, M. Ju, E. Cheung, J. Bradley, K. Nishijima, G. S. Robinson, A. P. Adamis, and D. T. Shima Inhibition of Platelet-Derived Growth Factor B Signaling Enhances the Efficacy of Anti-Vascular Endothelial Growth Factor Therapy in Multiple Models of Ocular Neovascularization Am. J. Pathol., June 1, 2006; 168(6): 2036 - 2053. [Abstract] [Full Text] [PDF]

				S. Dell, S. Peters, P. Muther, N. Kociok, and A. M. Joussen The Role of PDGF Receptor Inhibitors and PI3-Kinase Signaling in the Pathogenesis of Corneal Neovascularization Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 1928 - 1937. [Abstract] [Full Text] [PDF]

				E. Chavakis, A. Aicher, C. Heeschen, K.-i. Sasaki, R. Kaiser, N. El Makhfi, C. Urbich, T. Peters, K. Scharffetter-Kochanek, A. M. Zeiher, et al. Role of {beta}2-integrins for homing and neovascularization capacity of endothelial progenitor cells J. Exp. Med., January 3, 2005; 201(1): 63 - 72. [Abstract] [Full Text] [PDF]

				V. Poulaki, N. Mitsiades, F. E. Kruse, S. Radetzky, E. Iliaki, B. Kirchhof, and A. M. Joussen Activin A in the Regulation of Corneal Neovascularization and Vascular Endothelial Growth Factor Expression Am. J. Pathol., April 1, 2004; 164(4): 1293 - 1302. [Abstract] [Full Text] [PDF]

				T. Usui, S. Ishida, K. Yamashiro, Y. Kaji, V. Poulaki, J. Moore, T. Moore, S. Amano, Y. Horikawa, D. Dartt, et al. VEGF164(165) as the Pathological Isoform: Differential Leukocyte and Endothelial Responses through VEGFR1 and VEGFR2 Invest. Ophthalmol. Vis. Sci., February 1, 2004; 45(2): 368 - 374. [Abstract] [Full Text] [PDF]

				E. Sakurai, H. Taguchi, A. Anand, B. K. Ambati, E. S. Gragoudas, J. W. Miller, A. P. Adamis, and J. Ambati Targeted Disruption of the CD18 or ICAM-1 Gene Inhibits Choroidal Neovascularization Invest. Ophthalmol. Vis. Sci., June 1, 2003; 44(6): 2743 - 2749. [Abstract] [Full Text] [PDF]

				M. GOTTE Syndecans in inflammation FASEB J, April 1, 2003; 17(6): 575 - 591. [Abstract] [Full Text] [PDF]

				B. K. Ambati, A. Anand, A. M. Joussen, W. A. Kuziel, A. P. Adamis, and J. Ambati Sustained Inhibition of Corneal Neovascularization by Genetic Ablation of CCR5 Invest. Ophthalmol. Vis. Sci., February 1, 2003; 44(2): 590 - 593. [Abstract] [Full Text] [PDF]

				T. Kure, J.-H. Chang, T. Kato, E. Hernandez-Quintela, H. Ye, P. C.-S. Lu, L. M. Matrisian, D. Gatinel, S. Shapiro, F. Ghosheh, et al. Corneal Neovascularization after Excimer Keratectomy Wounds in Matrilysin-Deficient Mice Invest. Ophthalmol. Vis. Sci., January 1, 2003; 44(1): 137 - 144. [Abstract] [Full Text] [PDF]

				X. Ruan, J. Chodosh, M. C. Callegan, M. C. Booth, T. D. Lee, P. Kumar, M. S. Gilmore, and H. A. Pereira Corneal Expression of the Inflammatory Mediator CAP37 Invest. Ophthalmol. Vis. Sci., May 1, 2002; 43(5): 1414 - 1421. [Abstract] [Full Text] [PDF]

				M. Gotte, A. M. Joussen, C. Klein, P. Andre, D. D. Wagner, M. T. Hinkes, B. Kirchhof, A. P. Adamis, and M. Bernfield Role of Syndecan-1 in Leukocyte-Endothelial Interactions in the Ocular Vasculature Invest. Ophthalmol. Vis. Sci., April 1, 2002; 43(4): 1135 - 1141. [Abstract] [Full Text] [PDF]

				A. M. Joussen, W.-D. Beecken, Y. Moromizato, A. Schwartz, B. Kirchhof, and V. Poulaki Inhibition of Inflammatory Corneal Angiogenesis by TNP-470 Invest. Ophthalmol. Vis. Sci., October 1, 2001; 42(11): 2510 - 2516. [Abstract] [Full Text] [PDF]